BIOMAT Database Logo BIOMAT Database Logo

[Blood concentrations of futraful, uracil and 5-fluorouracil (5-FU) after UFT administration in the various reconstructions after gastrectomy. Saitama UFT Research Group]. 1992

Y Suda, and K Uchida, and H Okamura, and Y Oshima, and M Shimizu, and T Miyakawa, and S Okubo, and E Shiina, and Y Hosoda, and Y Tokura
Division of abdominal Surgery, Saitama Cancer Center Hospital, Japan.

The study was undertaken in the total of 58 gastric cancer patients among which 17 of Billroth (BI), 14 of Billroth II (B II) anastomosis after subtotal gastrectomy, and 7 of jejunal interposition, 9 of double tract and 11 of Roux en Y anastomosis after total gastrectomy were included. Blood samples were taken before 200 mg of per oral UFT administration and after 1, 2, 3, 5 and 7hrs. consecutively. The blood Futraful (FT) level in the total gastrectomy groups reached peak concentration within 1hr and kept in relatively high level during the observation period of 7hrs. The time to maximum FT concentration delayed in almost of B I and a few of B II patients. The concentration curves of uracil (URA) and 5-FU were similar in shape, revealing steep increase and decrease except B I anastomosis which showed gentle course. The plotted maximum concentrations of URA and 5-FU in the every type of reconstruction showed a significant correlation in the regression line. In the analysis of AUC, URA/FT was under 10%, suggesting the longer retention of the unmetabolite type of FT and early disappearance of URA. The ratio of 5-FU/FT was indifferent in each reconstruction. 5-FU/URA was higher in subtotal rather than total gastrectomy groups. From the data obtained, blood concentration of 5-FU after UFT administration was considered to depend on the emptying status in the gastrectomies. And moreover, it depended on blood URA level, since FT from which 5-FU was derived, was kept still sufficiently remained during observation period.

UI MeSH Term Description Entries
D011184 Postoperative Period The period following a surgical operation. Period, Postoperative,Periods, Postoperative,Postoperative Periods
D005472 Fluorouracil A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid. 5-FU,5-FU Lederle,5-FU Medac,5-Fluorouracil,5-Fluorouracil-Biosyn,5-HU Hexal,5FU,Adrucil,Carac,Efudex,Efudix,Fluoro-Uracile ICN,Fluoroplex,Fluorouracil Mononitrate,Fluorouracil Monopotassium Salt,Fluorouracil Monosodium Salt,Fluorouracil Potassium Salt,Fluorouracil-GRY,Fluorouracile Dakota,Fluorouracilo Ferrer Far,Fluoruracil,Fluracedyl,Flurodex,Haemato-FU,Neofluor,Onkofluor,Ribofluor,5 FU Lederle,5 FU Medac,5 Fluorouracil,5 Fluorouracil Biosyn,5 HU Hexal,Dakota, Fluorouracile,Fluoro Uracile ICN,Fluorouracil GRY,Haemato FU
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D005743 Gastrectomy Excision of the whole (total gastrectomy) or part (subtotal gastrectomy, partial gastrectomy, gastric resection) of the stomach. (Dorland, 28th ed) Gastrectomies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000713 Anastomosis, Roux-en-Y A Y-shaped surgical anastomosis of any part of the digestive system which includes the small intestine as the eventual drainage site. Roux-en-Y Anastomosis,Roux-en-Y Diversion,Roux-en-Y Loop,Anastomoses, Roux-en-Y,Anastomosis, Roux en Y,Diversion, Roux-en-Y,Diversions, Roux-en-Y,Loop, Roux-en-Y,Loops, Roux-en-Y,Roux en Y Anastomosis,Roux en Y Diversion,Roux en Y Loop,Roux-en-Y Anastomoses,Roux-en-Y Diversions,Roux-en-Y Loops
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D013274 Stomach Neoplasms Tumors or cancer of the STOMACH. Cancer of Stomach,Gastric Cancer,Gastric Neoplasms,Stomach Cancer,Cancer of the Stomach,Gastric Cancer, Familial Diffuse,Neoplasms, Gastric,Neoplasms, Stomach,Cancer, Gastric,Cancer, Stomach,Cancers, Gastric,Cancers, Stomach,Gastric Cancers,Gastric Neoplasm,Neoplasm, Gastric,Neoplasm, Stomach,Stomach Cancers,Stomach Neoplasm
D014498 Uracil One of four nucleotide bases in the nucleic acid RNA.
D017024 Chemotherapy, Adjuvant Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. Adjuvant Chemotherapy,Drug Therapy, Adjuvant,Adjuvant Drug Therapy

Related Publications

Y Suda, and K Uchida, and H Okamura, and Y Oshima, and M Shimizu, and T Miyakawa, and S Okubo, and E Shiina, and Y Hosoda, and Y Tokura
[FT, 5-FU and uracil concentrations of the blood, bile and tissue of hepatoma with liver cirrhosis after oral administration of UFT].
April 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Suda, and K Uchida, and H Okamura, and Y Oshima, and M Shimizu, and T Miyakawa, and S Okubo, and E Shiina, and Y Hosoda, and Y Tokura
[Study on the concentrations of 5-fluorouracil (5-FU), tegafur (ET) and uracil in bile: comparison of UFT or FT].
December 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Suda, and K Uchida, and H Okamura, and Y Oshima, and M Shimizu, and T Miyakawa, and S Okubo, and E Shiina, and Y Hosoda, and Y Tokura
[5-Fluorouracil, tegafur, and uracil concentrations in serum and tissue of the patients with hepatocellular carcinoma after UFT administration].
December 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Suda, and K Uchida, and H Okamura, and Y Oshima, and M Shimizu, and T Miyakawa, and S Okubo, and E Shiina, and Y Hosoda, and Y Tokura
[A study of urinary tegafur, 5-fluorouracil (5-FU) and uracil concentrations in the cases of gastric carcinoma for the confirmation of drug-taking compliance after UFT oral administration].
November 1992, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Suda, and K Uchida, and H Okamura, and Y Oshima, and M Shimizu, and T Miyakawa, and S Okubo, and E Shiina, and Y Hosoda, and Y Tokura
[5-FU, FT-207 and uracil concentrations in the serum and tissues of patients with cervical cancer after UFT oral administration].
February 1986, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Suda, and K Uchida, and H Okamura, and Y Oshima, and M Shimizu, and T Miyakawa, and S Okubo, and E Shiina, and Y Hosoda, and Y Tokura
[The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT].
August 1988, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Suda, and K Uchida, and H Okamura, and Y Oshima, and M Shimizu, and T Miyakawa, and S Okubo, and E Shiina, and Y Hosoda, and Y Tokura
[5-FU concentrations in the blood and tumor tissue after 5'-DFUR or UFT administration in the patients with uterine cervical cancer].
February 1995, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Suda, and K Uchida, and H Okamura, and Y Oshima, and M Shimizu, and T Miyakawa, and S Okubo, and E Shiina, and Y Hosoda, and Y Tokura
[Determination of 5-FU tissue concentrations after oral UFT administration in tumors of the head and neck].
January 1996, Gan to kagaku ryoho. Cancer & chemotherapy,
Y Suda, and K Uchida, and H Okamura, and Y Oshima, and M Shimizu, and T Miyakawa, and S Okubo, and E Shiina, and Y Hosoda, and Y Tokura
[The effect of gastrectomy on serum 5-FU concentrations of patients administered UFT per os].
April 1987, Gan no rinsho. Japan journal of cancer clinics,
Y Suda, and K Uchida, and H Okamura, and Y Oshima, and M Shimizu, and T Miyakawa, and S Okubo, and E Shiina, and Y Hosoda, and Y Tokura
[Tegafur and 5-FU concentrations in cancerous and normal tissues in nude mice after oral administration of UFT].
December 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!